Return to search

Investigation of mechanisms underlying synergism between prostanoid EP₃ receptor agonists and strong vasoconstrictor agents.

Le Gengyun. / Thesis submitted in: December 2002. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2003. / Includes bibliographical references (leaves 161-182). / Abstracts in English and Chinese. / Abstract --- p.i / Abbreviations --- p.v / Acknowledgements --- p.vii / Publications --- p.viii / Table of Contents --- p.ix / Chapter Chapter 1 --- INTRODUCTION --- p.1 / Chapter 1. --- Vasoconstrictors --- p.1 / Chapter 1.1 --- An overview of vascular smooth muscle contraction --- p.1 / Chapter 1.2 --- Strong and weak vasoconstrictors --- p.5 / Chapter 1.2.1 --- Mechanisms involved in TP receptor vasoconstriction --- p.6 / Chapter 1.2.1.1 --- Brief introduction to the TP receptor --- p.6 / Chapter 1.2.1.2 --- Second messenger systems --- p.6 / Chapter 1.2.1.3 --- G-protein-linked pathways --- p.7 / Chapter 1.2.1.3.1 --- G proteins --- p.7 / Chapter 1.2.1.3.2 --- G-protein-linked TP receptor signal transduction --- p.8 / Chapter 1.2.2 --- Mechanisms involved in α1-adrenoceptor vasoconstriction --- p.8 / Chapter 1.2.2.1 --- Brief introduction to the α1-adrenoceptor --- p.8 / Chapter 1.2.2.2 --- Second messenger systems --- p.9 / Chapter 1.2.2.3 --- G-protein-linked α-adrenoceptor signal transduction --- p.9 / Chapter 1.3 --- Prostanoid EP3 receptor agonists (weak vasoconstrictors) --- p.10 / Chapter 1.3.1 --- Prostanoids --- p.10 / Chapter 1.3.1.1 --- Biochemical characteristics of prostanoids --- p.10 / Chapter 1.3.1.1.1 --- Biosynthesis of prostanoids --- p.10 / Chapter 1.3.1.1.2 --- Metabolism of prostanoids --- p.11 / Chapter 1.3.1.2 --- Prostanoid receptors --- p.13 / Chapter 1.3.1.2.1 --- Structures --- p.13 / Chapter 1.3.1.2.2 --- Current Status of Classification --- p.14 / Chapter 1.3.1.2.3 --- Signal transduction --- p.16 / Chapter 1.3.1.2.4 --- Distribution --- p.18 / Chapter 1.3.1.2.5 --- Physiological functions --- p.18 / Chapter 2. --- Interactions between vasoconstrictors --- p.19 / Chapter 2.1 --- Cross-talk between G-protein-coupled receptors --- p.19 / Chapter 2.1.1 --- Cross-talk between different receptor families --- p.19 / Chapter 2.1.2 --- Cross-talk between subtypes of the same receptor family --- p.21 / Chapter 2.1.3 --- Cross-talk at the effector level --- p.23 / Chapter 2.2 --- Proposed pathways involved in synergistic interactions --- p.24 / Chapter 2.2.1 --- Rho and Rho-associated kinase --- p.24 / Chapter 2.2.1.1 --- Rho family and its identification --- p.24 / Chapter 2.2.1.2 --- Mechanism(s) of Rho contribution in vasoconstriction --- p.25 / Chapter 2.2.1.3 --- Interactions between Rho and other pathways --- p.26 / Chapter 2.2.2 --- Receptor tyrosine kinases --- p.29 / Chapter 2.2.2.1 --- RTK family --- p.29 / Chapter 2.2.2.2 --- Activation of RTKs --- p.29 / Chapter 2.2.2.3 --- Mechanism(s) of RTK contribution in vasoconstriction --- p.30 / Chapter 2.2.2.4 --- Interactions between RTKs and MAPKs --- p.31 / Chapter 2.2.3 --- Mitogen-activated protein kinase --- p.34 / Chapter 2.2.3.1 --- p38 MAPK --- p.35 / Chapter 2.2.3.2 --- JNK MAPK --- p.35 / Chapter 2.2.3.3 --- ERK MAPK --- p.36 / Chapter 2.2.3.4 --- Interactions between MAPK and GPCRs --- p.37 / Chapter Chapter 2 --- FORCE MEASUREMENT SYSTEM --- p.41 / Chapter 1. --- Introduction --- p.41 / Chapter 2. --- Materials --- p.41 / Chapter 2.1 --- Drugs --- p.41 / Chapter 2.2 --- Chemicals --- p.41 / Chapter 2.3 --- Solutions --- p.46 / Chapter 3. --- Methods --- p.46 / Chapter 3.1 --- Isolated smooth muscle preparations and organ bath set-up --- p.46 / Chapter 3.2 --- Data analysis --- p.47 / Chapter Chapter 3 --- VASOCONSTRICTORS AND THEIR INTERACTIONS --- p.48 / Chapter 1. --- Introduction --- p.48 / Chapter 2. --- Materials and Methods --- p.48 / Chapter 2.1 --- Materials --- p.48 / Chapter 2.2 --- Methods --- p.51 / Chapter 2.2.1 --- Isolated tissue preparations --- p.51 / Chapter 2.2.2 --- Experimental protocols --- p.51 / Chapter 2.2.3 --- Statistical analysis --- p.52 / Chapter 3. --- Results --- p.55 / Chapter 3.1 --- Typical vasoconstrictor profiles of agonists --- p.55 / Chapter 3.1.1 --- Sulprostone contraction --- p.55 / Chapter 3.1.2 --- U-46619 contraction --- p.55 / Chapter 3.1.3 --- Phenylephrine contraction --- p.56 / Chapter 3.2 --- Synergistic interactions between sulprostone and strong vasoconstrictors --- p.58 / Chapter 3.2.1 --- Enhancement of U-46619 response by sulprostone --- p.58 / Chapter 3.2.2 --- Enhancement of phenylephrine response by sulprostone --- p.58 / Chapter 3.2.3 --- Enhancement of sulprostone response by phenylephrine --- p.58 / Chapter Chapter 4 --- INVESTIGATION OF PATHWAYS INVOLVED IN EP3 AGONIST- INDUCED VASOCONSTRICTION --- p.64 / Chapter 1. --- Introduction --- p.64 / Chapter 2. --- Materials and methods --- p.65 / Chapter 2.1 --- Materials --- p.65 / Chapter 2.2 --- Methods --- p.65 / Chapter 2.2.1 --- Isolated tissue preparations --- p.65 / Chapter 2.2.2 --- Experimental protocols --- p.65 / Chapter 2.2.3 --- Statistical analysis --- p.69 / Chapter 3. --- Results --- p.70 / Chapter 3.1 --- Effects of tyrosine kinase inhibitors --- p.70 / Chapter 3.2 --- Effects of MAPK inhibitors --- p.82 / Chapter 3.2.1 --- Effects of MAPK inhibitors on U-46619 responses --- p.82 / Chapter 3.2.2 --- Effects of MAPK inhibitors on sulprostone responses --- p.91 / Chapter 3.2.3 --- Effects of MAPK inhibitors on phenylephrine responses --- p.100 / Chapter 3.3 --- Effects of Rho-kinase inhibitors --- p.104 / Chapter Chapter 5 --- TRANSFECTED CELL LINE SYSTEM --- p.111 / Chapter 1. --- Introduction --- p.111 / Chapter 2. --- Materials and methods --- p.114 / Chapter 2.1 --- Materials --- p.114 / Chapter 2.1.1 --- Plasmids and vectors --- p.114 / Chapter 2.1.2 --- Radioactive agents --- p.114 / Chapter 2.1.3 --- Chemicals --- p.114 / Chapter 2.1.4 --- Restriction digest enzymes --- p.115 / Chapter 2.1.5 --- "Culture media, buffers and solutions" --- p.115 / Chapter 2.1.5.1 --- Culture media / Chapter 2.1.5.2 --- Buffers and solutions --- p.115 / Chapter 2.2 --- Methods --- p.116 / Chapter 2.2.1 --- Transfected cell lines --- p.116 / Chapter 2.2.1.1 --- Subcloning of hEP3-1 receptor and hTP receptor cDNA --- p.116 / Chapter 2.2.1.1.1 --- Plasmid recovery / Chapter 2.2.1.1.2 --- Preparation of competent cells --- p.116 / Chapter 2.2.1.1.3 --- Transformation of competent cells --- p.117 / Chapter 2.2.1.1.4 --- Extraction of DNA by QIAGEN Plasmid Mini Kit --- p.117 / Chapter 2.2.1.1.5 --- Restriction enzymes digestion and dephosphorylation --- p.117 / Chapter 2.2.1.1.6 --- DNA recovery and ligation / Chapter 2.2.1.1.7 --- Positive recombinant DNA selection --- p.119 / Chapter 2.2.1.2 --- Cell culture --- p.119 / Chapter 2.2.1.3 --- Transient transfection of CHO cells --- p.121 / Chapter 2.2.1.4 --- Mesurement of adenylate cyclase activity --- p.121 / Chapter 2.2.1.4.1 --- Preparation of columns --- p.121 / Chapter 2.2.1.4.2 --- [3H]-cAMP assays --- p.122 / Chapter 2.2.1.5 --- Measurement of phospholipase C activity --- p.122 / Chapter 2.2.1.5.1 --- Preparation of columns --- p.123 / Chapter 2.2.1.5.2 --- [3H]-inositol phosphate assay --- p.123 / Chapter 2.2.2 --- Data analysis --- p.124 / Chapter 3. --- Results --- p.125 / Chapter 3.1 --- Subcloning of hEP3-1and hTPα receptor cDNA into expression vectors --- p.125 / Chapter 3.2 --- Measurement of cAMP and IP production in transfected CHO cells --- p.133 / Chapter 3.2.1 --- Effect of varying receptor cDNA concentration on agonist-stimulated [3H]-cAMP and [3H]-IP production in transiently transfected CHO cells --- p.133 / Chapter 3.2.2 --- Effect of agonists on intracellular [3H]-IP or [3H]-cAMP productionin CHO cells transfected with hTPα or hEP3-1 --- p.133 / Chapter 3.3 --- Summary --- p.134 / Chapter Chapter 6 --- GENERAL DISCUSSION AND CONCLUSIONS --- p.137 / Chapter 1. --- Vasoconstrictors and their interactions --- p.137 / Chapter 1.1 --- Vasoconstrictors --- p.137 / Chapter 1.2 --- Synergism --- p.138 / Chapter 2. --- Investigation of possible pathways --- p.140 / Chapter 2.1 --- Rho-associated kinase --- p.140 / Chapter 2.2 --- Receptor tyrosine kinase --- p.147 / Chapter 2.3 --- Mitogen-activated protein kinase (MAPK) --- p.151 / Chapter 3. --- Effect of vehicles --- p.155 / Chapter 4. --- Biochemical studies in transfected CHO cells --- p.157 / Chapter 5. --- Conclusions --- p.158 / Appendix I --- p.159 / Buffers and Solutions used in transfected system --- p.159 / Chapter 1. --- Buffers --- p.159 / Chapter 2. --- Solutions --- p.159 / REFERENCES --- p.161

Identiferoai:union.ndltd.org:cuhk.edu.hk/oai:cuhk-dr:cuhk_324481
Date January 2003
ContributorsLe, Gengyun., Chinese University of Hong Kong Graduate School. Division of Pharmacology.
Source SetsThe Chinese University of Hong Kong
LanguageEnglish, Chinese
Detected LanguageEnglish
TypeText, bibliography
Formatprint, xii, 182 leaves : ill. (some col.) ; 30 cm.
RightsUse of this resource is governed by the terms and conditions of the Creative Commons “Attribution-NonCommercial-NoDerivatives 4.0 International” License (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Page generated in 0.0032 seconds